HMN 2025: How Childhood cancer catalog opens door to pediatric immunotherapy

A unique facility in Melbourne containing hundreds of childhood cancer tissue samples has produced a first-of-its-kind catalog of pediatric cancers to help identify how the immune system can target each one.

Pediatric cancer is the leading cause of disease-related death in children throughout the Western world and immunotherapy options are limited, because childhood cancers often don’t respond the same way as adult cancers to the same treatments.

The Children’s Cancer Model Atlas, or CCMA, located at Hudson Institute of Medical Research, is the world’s largest collection of pediatric cancer cell lines, giving researchers the chance to test and analyze potential treatments using cutting-edge AI techniques.

Researchers have now examined more than 200 high-risk pediatric cancer cell lines in the CCMA’s collection to identify a crucial characteristic of each one, known as the HLA type and potential neoantigens it presents to the immune system.

Cancer catalog provides immunotherapy targets

Their analysis has been published in the journal iScience, and senior author, Dr. Claire Sun, said it represents a detailed resource of high-potential immune targets in childhood cancers.

“Human leukocyte antigens (HLA) are proteins on the surface of cells that the immune system uses to distinguish between ‘self’ and ‘non-self,'” Dr. Sun said. “Using this information, we predicted which neoantigens each cancer model might produce and present.

“Neoantigens are small, abnormal protein pieces formed when cancer cells mutate, and different HLA types can present different neoantigens to the immune system. Knowing the HLA type helps us determine which neoantigens can actually be recognized.”

The impact of his research, according to research assistant Yiwen Guan, is to help researchers identify which tumors have actionable antigens which make them good candidates for immunotherapy.

“Our research provides valuable support for the research community by guiding the development of safer, more effective immunotherapies for children,” she said.

About childhood cancer

• In Australia, more than 1,000 children and adolescents are diagnosed with cancer each year and 5,600 are undergoing treatment.
• On average, about three children or adolescents die every week from cancer in Australia.
• For every 10 children diagnosed, two will not survive; and those who do suffer long-term (sometimes life-long) health issues because current therapies can affect children’s growing bodies.
• The development of more targeted and less toxic treatments for children with cancer is crucial to improve survival rates and reduce long-term treatment-related side effects.

About the Childhood Cancer Model Atlas

• The CCMA includes more than 400 high-risk pediatric cancer cell lines.
• This unique repository was established through the collaboration of nearly 50 leading cancer research institutes, universities, and academic medical centers worldwide.
• The CCMA provides an open-source facility to cancer researchers globally, and is available to every pediatric oncologist and childhood cancer researcher.
• Using the CCMA, researchers can have potential treatments tested and analyzed using cutting-edge AI techniques.
• By facilitating shared “big data,” the CCMA is creating a pediatric cancer catalog to accelerate the discovery of new therapies and biomarkers for childhood cancers.

The content is provided for information purposes only.